NIAID, Half-Matched Hematopoietic Stem Cell Transplantation in Early Phase 1 Trial for CGD Patients Followed for Long-Term
Clinical Status and Key Objectives
The NCT03910452 trial, led by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is an early Phase 1 single-arm study applying haploidentical hematopoietic stem cell transplantation (HSCT) in patients with chronic granulomatous disease (CGD). The trial began in October 2019, enrolled four patients, and as of March 2026, enrollment has been completed, though follow-up is ongoing, with the study expected to conclude in June 2034. The primary endpoint combines marrow chimerism exceeding 50% at 30 days, 100 days, 6 months, and 12 months post-transplant with the avoidance of severe graft-versus-host disease (GvHD), aiming to evaluate clinically sustainable immune reconstitution beyond simple engraftment.
Drug and Transplant Design
The conditioning regimen includes Campath (alemtuzumab, a CD52-targeting antibody), Busulfex·Myleran (busulfan, a DNA alkylating agent), and low-dose total body irradiation, followed by Cytoxan (cyclophosphamide, a DNA alkylating prodrug) to suppress allogeneic T cells post-transplant. The reduced-intensity conditioning, including alemtuzumab for five days and intravenous busulfan for three days, is designed to simultaneously achieve immune cell depletion and marrow space expansion while minimizing long-term toxicity. Although Campath is a Genzyme product under Sanofi (SNY), it is not approved for CGD transplant conditioning. The value of this study lies in the protocol combining a haploidentical donor and post-transplant cyclophosphamide, rather than in individual drugs.
Existing Treatment and Competitive Landscape
Standard CGD management includes antimicrobial and antifungal prophylaxis and Actimmune (interferon gamma-1b, which activates IFNGR1·IFNGR2 signaling). The FDA approved Actimmune in December 20, 1990, for reducing the frequency and severity of severe infections. Amgen (AMGN), which owns Actimmune, reports this product alongside other ultra-rare disease products in its financial disclosures, and revenue from this product line was not separately disclosed in 2025. The curative treatment competition includes HLA-matched allogeneic HSCT and autologous CD34-positive cell-based gene therapy. Généthon's G1XCGD lentiviral therapy is in Phase 1/2, and Prime Medicine (PRME)'s PM359 prime editing therapy targeting NCF1 is also in Phase 1/2.
Patient, Market, and Investment Implications
The global CGD management market is estimated to be approximately USD 1.44 billion in 2025, but actual commercial opportunities are limited by the number of rare disease patients and transplant-eligible centers. Haploidentical related donors are more accessible than fully matched donors, and if safe engraftment is confirmed, this approach could expand treatment access for patients previously excluded due to donor shortages. However, as an early Phase 1 trial with only four enrolled patients and no published results, the current investment focus is on marrow chimerism exceeding 50%, severe GvHD, transplant-related mortality, viral reactivation, and long-term event-free survival data.
Due to the small sample size of four patients in this early Phase 1 trial, short-term commercial value is less important than safety signals and protocol reproducibility. If haploidentical HSCT maintains marrow chimerism above 50% without severe GvHD in the USD 1.44 billion CGD management market in 2025, it could alleviate the key bottleneck of HLA-matched donor shortages. For researchers, the data will validate the balance of reduced-intensity conditioning with Campath, Busulfex, and Cytoxan, and post-transplant immune modulation. For the industry, it could serve as a basis to reshape the competitive landscape between Actimmune-centered chronic management and curative treatments. Mid-to-long-term competitors include Généthon's G1XCGD Phase 1/2 and Prime Medicine (PRME)'s PM359 Phase 1/2, with autologous gene therapy posing direct technical pressure due to its ability to avoid GvHD.
Source: ClinicalTrials.gov (api_ct)